Laman UtamaHELP • NASDAQ
add
Cybin Inc
Tutup sebelumnya
$7.61
Julat hari
$7.22 - $8.10
Julat tahun
$5.76 - $8.97
Bilangan Purata
520.82K
Nisbah P/E
-
Hasil dividen
-
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (CAD) | Mac 2025info | Perubahan T/T |
|---|---|---|
Hasil | — | — |
Perbelanjaan pengendalian | 33.24J | 31.95% |
Pendapatan bersih | -30.58J | -43.25% |
Margin untung bersih | — | — |
Pendapatan bagi setiap syer | -1.46 | -92.11% |
EBITDA | -33.19J | -32.03% |
Kadar cukai berkesan | — | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (CAD) | Mac 2025info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 135.02J | -35.39% |
Jumlah aset | 258.62J | -14.37% |
Jumlah liabiliti | 21.42J | 112.14% |
Jumlah ekuiti | 237.20J | — |
Syer tertunggak | 23.03J | — |
Harga kepada buku | 0.69 | — |
Pulangan pada aset | -32.45% | — |
Pulangan pada modal | -34.81% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (CAD) | Mac 2025info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -30.58J | -43.25% |
Tunai daripada operasi | -21.11J | -1.96% |
Tunai daripada pelaburan | -1.08J | -404.19% |
Tunai daripada pembiayaan | 20.98J | -89.01% |
Perubahan bersih dalam tunai | -1.27J | -100.75% |
Aliran tunai bebas | -11.14J | 12.30% |
Perihal
Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that is developing psychedelic drugs as medicines.
The company's drug candidates include psilocybin, HLP002, HLP003, HLP004, HLP005, and HLP006. Another drug that the company has developed is CYB210010.
As of January 2025, HLP003 is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 to have reached this late stage of clinical development.
In 2020, Helus Pharma acquired psychedelic pharmaceutical company Adelia Therapeutics. Helus Pharma was originally known as Cybin but changed its name in December 2025. Wikipedia
Diasaskan
2019
Ibu pejabat
Tapak web
Pekerja
50
